PRPH ProPhase Labs, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 868278 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY138.9%
TTM net income YoY45.8%
TTM EPS YoY91.5%
Revenue 3-yr CAGR-63.4%
Net income 3-yr CAGR—
Margins
Gross margin16.8%
Operating margin-404.5%
Net margin-583.9%
FCF margin—
EBITDA margin-320.1%
Returns
ROE-539.7%
ROA-45.2%
ROIC (approx.)-302.2%
Asset turnover0.08x
Leverage & solvency
Liabilities / assets105.4%
Debt / equity—
Current ratio0.05x
Interest coverage-2.15x
Cash quality & payout
Operating cash flow / net income0.25x
Accruals ratio-34.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $4.34M | $6.77M | $34.98M | $122.65M | $79.04M |
| Cost of revenue | $2.96M | $6.92M | $19.43M | $51.99M | $37.05M |
| Gross profit | $1.38M | -$150,000 | $15.56M | $70.65M | $41.99M |
| R&D expense | $107,000 | $594,000 | $1.40M | $652,000 | $520,000 |
| SG&A expense | $19.32M | $37.88M | $33.44M | $34.38M | $22.49M |
| Operating income | -$18.05M | -$38.63M | -$21.22M | $23.59M | $9.80M |
| Interest expense | $6.93M | $3.35M | $1.27M | $764,000 | $1.15M |
| Pretax income | -$23.39M | -$42.33M | -$22.40M | $22.91M | $5.30M |
| Income tax | $0 | $7.20M | -$6.02M | $4.45M | -$968,000 |
| Net income | -$14.74M | -$53.36M | -$16.78M | $18.46M | $6.27M |
| EBITDA | -$13.21M | -$32.44M | -$15.17M | $28.31M | $13.04M |
| EPS (basic) | -1.74 | -26.68 | -0.98 | 1.17 | 0.41 |
| EPS (diluted) | -1.74 | -26.68 | -0.98 | 1.02 | 0.40 |
| Dividends declared per share | — | — | — | — | 0.30 |
| Weighted avg. shares (diluted) | 8.49M | 2.00M | 17.21M | 18.65M | 18.39M |
| Banking | |||||
| Provision for credit losses | — | $0 | $91,000 | $6.16M | — |
| Balance sheet | |||||
| Cash & equivalents | $90,000 | $678,000 | $1.61M | $9.11M | $8.66M |
| Short-term investments | $0 | $3.13M | $3.13M | $8.33M | $8.78M |
| Receivables | $1.54M | $20.06M | $35.81M | $37.05M | $37.71M |
| Inventory | $70,000 | $1.14M | $2.29M | $3.98M | $4.60M |
| Current assets | $3.15M | $30.64M | $47.59M | $60.83M | $61.32M |
| PP&E, net | $2.03M | $7.50M | $10.33M | $7.29M | $5.95M |
| Goodwill | $3.97M | $5.23M | $5.23M | $5.71M | $5.71M |
| Intangibles | $7.17M | $9.75M | $12.33M | $8.47M | $10.85M |
| Total assets | $59.87M | $63.20M | $91.93M | $87.65M | $89.30M |
| Current liabilities | $53.08M | $32.13M | $20.86M | $16.07M | $15.52M |
| Short-term debt | — | $3.21M | $0 | — | — |
| Long-term debt | — | — | $2.92M | $0 | — |
| Total debt | — | — | $2.92M | $0 | — |
| Total liabilities | $56.36M | $55.85M | $42.54M | $24.02M | $30.67M |
| Shareholders' equity | $3.51M | $7.35M | $49.38M | $63.63M | $58.63M |
| Net debt | — | — | $1.31M | -$9.11M | — |
| Shares outstanding | 8.97M | 2.99M | 18.05M | 16.21M | 15.49M |
| Cash flow statement | |||||
| Operating cash flow | -$8.34M | -$17.54M | -$11.89M | $28.55M | -$13.62M |
| Capital expenditure | $0 | $906,000 | $2.08M | $3.92M | $4.23M |
| Free cash flow | -$8.34M | -$18.44M | -$13.97M | $24.63M | -$17.85M |
| Investing cash flow | $920,000 | $2.42M | -$1.37M | -$2.08M | -$19.67M |
| Financing cash flow | $6.84M | $14.19M | $5.76M | -$26.02M | $35.13M |
| Depreciation & amortization | $4.83M | $6.19M | $6.05M | $4.72M | $3.23M |
| Stock-based compensation | $1.89M | $3.64M | $3.54M | $3.99M | $3.18M |
| Dividends paid | — | — | $0 | $9.35M | $4.55M |
| Share buybacks | — | $0 | $588,000 | $2.15M | $917,000 |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.